Efficacy and safety of bio‐chemotherapy with dacarbazine plus interleukin‐2 in patients with unresectable malignant melanoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1743-7563|11|4|314-318

ISSN： 1743-7555

Source： ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.11, Iss.4, 2015-12, pp. : 314-318

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interleukin-2-Based Biochemotherapy for Patients with Stage IV Melanoma: Long-Term Survivors Outside a Clinical Trial Setting

By  

Oncology, Vol. 73, Iss. 1-2, 2008-03 ,pp. : 33-40

Karger

Access to resources Recommend Favorite

Dacarbazine, Nimustine Hydrochloride, Cisplatin and Tamoxifen Combination Chemotherapy for Advanced Malignant Melanoma

By  

THE JOURNAL OF DERMATOLOGY, Vol. 26, Iss. 8, 1999-08 ,pp. : 489-493

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-12 ,pp. : 123-126

Karger

Access to resources Recommend Favorite

Docetaxel in Combination with Dacarbazine in Patients with Advanced Melanoma

By  

Oncology, Vol. 63, Iss. 4, 2002-11 ,pp. : 333-337

Karger

Access to resources Recommend Favorite

Myelodysplastic Syndrome Following Treatment of Malignant Melanoma with Vincristine, ACNU, and Dacarbazine

By  

THE JOURNAL OF DERMATOLOGY, Vol. 27, Iss. 3, 2000-03 ,pp. : 178-180

John Wiley & Sons Inc

Access to resources Recommend Favorite